GB0509224D0 - Inhibitors of intracellular enzymatic activity - Google Patents

Inhibitors of intracellular enzymatic activity

Info

Publication number
GB0509224D0
GB0509224D0 GBGB0509224.2A GB0509224A GB0509224D0 GB 0509224 D0 GB0509224 D0 GB 0509224D0 GB 0509224 A GB0509224 A GB 0509224A GB 0509224 D0 GB0509224 D0 GB 0509224D0
Authority
GB
United Kingdom
Prior art keywords
inhibitors
enzymatic activity
intracellular enzymatic
intracellular
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0509224.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chroma Therapeutics Ltd
Original Assignee
Chroma Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chroma Therapeutics Ltd filed Critical Chroma Therapeutics Ltd
Priority to GBGB0509224.2A priority Critical patent/GB0509224D0/en
Publication of GB0509224D0 publication Critical patent/GB0509224D0/en
Priority to PCT/GB2006/001644 priority patent/WO2006117570A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
GBGB0509224.2A 2005-05-05 2005-05-05 Inhibitors of intracellular enzymatic activity Ceased GB0509224D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0509224.2A GB0509224D0 (en) 2005-05-05 2005-05-05 Inhibitors of intracellular enzymatic activity
PCT/GB2006/001644 WO2006117570A1 (en) 2005-05-05 2006-05-04 Quinoline derivatives as kinase enzyme inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0509224.2A GB0509224D0 (en) 2005-05-05 2005-05-05 Inhibitors of intracellular enzymatic activity

Publications (1)

Publication Number Publication Date
GB0509224D0 true GB0509224D0 (en) 2005-06-15

Family

ID=34685156

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0509224.2A Ceased GB0509224D0 (en) 2005-05-05 2005-05-05 Inhibitors of intracellular enzymatic activity

Country Status (2)

Country Link
GB (1) GB0509224D0 (en)
WO (1) WO2006117570A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500008A (en) 2004-01-16 2005-08-16 QUINOLINE INTERMEDIARIES AS INHIBITORS OF THIROSINE KINASE RECEPTORS AND THE SYNTHESIS OF THE SAME
WO2006040520A1 (en) 2004-10-12 2006-04-20 Astrazeneca Ab Quinazoline derivatives
US20090215800A1 (en) * 2005-05-05 2009-08-27 Chroma Therapeutics Ltd Enzyme and Receptor Modulation
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
UY30183A1 (en) 2006-03-02 2007-10-31 Astrazeneca Ab QUINOLINE DERIVATIVES
GEP20135728B (en) 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors
PE20090717A1 (en) 2007-05-18 2009-07-18 Smithkline Beecham Corp QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
NZ620174A (en) 2009-09-16 2016-08-26 Celgene Avilomics Res Inc Protein kinase conjugates and inhibitors
AU2010339456A1 (en) 2009-12-30 2012-07-05 Celgene Avilomics Research, Inc. Ligand-directed covalent modification of protein
RS55500B1 (en) 2012-06-26 2017-05-31 Bayer Pharma AG N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products
WO2014127214A1 (en) 2013-02-15 2014-08-21 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
CA2900680C (en) 2013-02-20 2021-08-10 Kala Pharmaceuticals, Inc. Quinoline and quinazoline compounds and uses thereof for treating and/or preventing diseases
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
MX355330B (en) 2013-11-01 2018-04-16 Kala Pharmaceuticals Inc CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS and USES THEREOF.
US10752640B2 (en) 2014-08-01 2020-08-25 Nuevolution A/S Compounds active towards bromodomains
WO2018048747A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10336767B2 (en) 2016-09-08 2019-07-02 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10392399B2 (en) 2016-09-08 2019-08-27 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
JP2021515767A (en) 2018-03-07 2021-06-24 バイエル・アクチエンゲゼルシヤフト Identification and use of ERK5 inhibitors
US20220227729A1 (en) 2019-05-21 2022-07-21 Bayer Aktiengesellschaft Identification and use of kras inhibitors
CN112778217B (en) * 2019-11-08 2024-01-26 沈阳化工研究院有限公司 Quinazoline compound and application thereof
WO2021152113A1 (en) 2020-01-31 2021-08-05 Bayer Aktiengesellschaft Substituted 2,3-benzodiazepines derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1218356A1 (en) * 1999-09-21 2002-07-03 AstraZeneca AB Quinazoline compounds and pharmaceutical compositions containing them
US6977259B2 (en) * 2000-01-28 2005-12-20 Astrazeneca Ab Quinoline derivatives and their use as aurora 2 kinase inhibitors
AUPQ841300A0 (en) * 2000-06-27 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. New aminoalcohol derivatives
BRPI0507373A (en) * 2004-01-23 2007-07-10 Amgen Inc compounds and method of use
WO2005097137A2 (en) * 2004-03-31 2005-10-20 The Scripps Research Institute Advanced quinazoline based protein kinase inhibitors

Also Published As

Publication number Publication date
WO2006117570A1 (en) 2006-11-09

Similar Documents

Publication Publication Date Title
GB0509224D0 (en) Inhibitors of intracellular enzymatic activity
HK1225722A1 (en) Inhibitors of kinase activity
SI1848718T1 (en) Inhibitors of e1 activating enzymes
HRP20130429T1 (en) Inhibitors of akt activity
EP1968568A4 (en) INHIBITORS OF Akt ACTIVITY
AP2008004442A0 (en) Inhibitors of AKT activity
EP1850843A4 (en) Inhibitors of akt activity
ZA200802585B (en) Pyridopyrimidinone inhibitors of Pl3Kα
IL190292A0 (en) PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka
IL189975A0 (en) Methods of modulating neurotrophin-mediated activity
EP1871376A4 (en) Inhibitors of akt activity
ZA200706345B (en) Amino-pyridines as inhibitors of ß-secretase
EP1720855A4 (en) Inhibitors of akt activity
EP1784175A4 (en) Inhibitors of akt activity
EP1737861A4 (en) Inhibitors of akt activity
EP1827436A4 (en) Inhibitors of akt activity
EP2068941A4 (en) Improvement of arginase levels/activity
EP1824849A4 (en) Inhibitors of akt activity
EP1948185A4 (en) Inhibitors of akt activity
EP1923402A4 (en) Method for determination of enzymatic activity
IL177647A0 (en) Use of enzyme
EP1946106A4 (en) Methods for indentification of inhibitors of enzyme activity
ZA200803485B (en) Inhibitors of akt activity
ZA200709762B (en) Inhibitors of Akt activity
GB2414071B (en) Determination of antioxidant activity

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)